Chromosome instability

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
星期五, 三月 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

Retrieved on: 
星期二, 四月 4, 2023
SON, CIN, Intellectual property, Biotechnology, Genetic engineering, CRC, CIMP, Phageome, Microsatellite instability, Bacteriophage, Cancer, Ageing, BFT, Statistics, Research, Attention, Colon, Patient, Organoid, Colorectal cancer, Bacteroides fragilis, MSI, Intron, CpG, Recurrence, Smoking, Chromosome instability, Metastasis, Pharmaceutical industry, Vaccine

BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

Key Points: 
  • BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.
  • P18-BE3CRC is a drug candidate of PHAGERIA® platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) effective for cancer control.
  • As comparing the cases with or without administering PHAGERIA® candidate, it was confirmed that administering PHAGERIA® candidate significantly inhibited tumorigenesis.
  • Mr. YOON, Kyung-won, CEO of iNtRON said that "We will accelerate follow-up research and development through partnerships with global companies.

 Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021

Retrieved on: 
星期四, 四月 8, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Oncology, American Association for Cancer Research, Cancer, Chromosome instability, Clinical medicine, Health, Plenary, Metástasis

Volastra Therapeutics today announced that Co-founder Samuel Bakhoum, M.D., Ph.D., and Scientific Advisory Board Member David Pellman, M.D., will both deliver plenary presentations at the April session of the American Association for Cancer Research (AACR) Annual Meeting 2021.

Key Points: 
  • Volastra Therapeutics today announced that Co-founder Samuel Bakhoum, M.D., Ph.D., and Scientific Advisory Board Member David Pellman, M.D., will both deliver plenary presentations at the April session of the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • The plenary session, titled Mechanisms, Impact, and Exploitation of Cancer Chromosomal Instability, is dedicated to exploring a key driver of tumor progression.
  • Volastra is building on this groundbreaking work into the biology of chromosomal instability, which will be shared throughout the plenary session, to develop new therapies for metastatic cancer.
  • Its importance to the future of cancer treatment is underscored by AACRs decision to devote a leading plenary session to the topic, said Dr. Bakhoum.

Extra chromosomes in cancers can be good or bad

Retrieved on: 
星期一, 二月 24, 2020
Branches of biology, Genetics, Chromosomal abnormalities, Cytogenetics, Chromosomes, Oncology, Aneuploidy, Cancer, Chromosome, Anaphase lag, Chromosome instability

A tumor cell can contain an abundance of DNA mutations and most have the wrong number of chromosomes.

Key Points: 
  • A tumor cell can contain an abundance of DNA mutations and most have the wrong number of chromosomes.
  • As cancer progresses, so does aneuploidy.Some advanced tumors can harbor cells that have accumulated more than 100 chromosomes, instead of 46 in normal cells.
  • High levels of aneuploidy are associated with aggressive cancers and a poor prognosis for patients.
  • While survival is poorest among patients whose cancers have a high level of aneuploidy overall, the team identified certain chromosomes for which extra copies were associated with increased survival.